Crinetics Pharmaceuticals (CRNX) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company overview and pipeline focus

• Celebrated 15 years, focusing on small molecules for endocrine disorders, with a matured pipeline beyond lead asset paltusotine.

• Atumelnant is in development for congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's disease.

• Early R&D programs are expected to enter the clinic within 12–18 months, aiming to build a broad endocrine franchise.

Paltusotine for acromegaly: clinical results and launch plans

• Paltusotine is an oral alternative to painful injectable therapies, offering rapid, durable effects and fewer breakthrough symptoms.

• Phase III PATHFNDR-1 showed 83% IGF-1 response vs. 4% placebo; PATHFNDR-2 showed 56% response vs. 5% placebo, meeting all endpoints.

• NDA submission is on track for end of 2024, with no major outstanding factors.

• Launch strategy targets endocrinologists, patient empowerment, and payer engagement, with a planned sales force of 25–30.

• Commercial build-out is measured, with sales hiring to follow positive regulatory signals.

Paltusotine for carcinoid syndrome: progress and next steps

• Phase II data showed >60% reduction in flushing and bowel movement symptoms.

• Regulatory engagement is underway to finalize phase III design, aiming for broad patient inclusion and clear symptom-based endpoints.

• Study initiation is planned by year-end, with overlap in physician base supporting commercial synergy.